Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No adjuvant chemotherapy trial has ever been run in appendiceal adenocarcinoma.
Which patients with peritoneal disease benefit from HIPEC is defined only by retrospective series.
Nothing recorded yet.
Nothing recorded yet.
Background: Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Signet ring cell carcinoma has no effective therapy.
Mucinous tumours respond poorly to standard chemotherapy and have no targeted option.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.